Table I.
Baseline Comparison of Intervention and Control Groups
| Totala, N=105 n (%) | Intervention, N=51 n (%) | Control, N=54 n (%) | p- valueb | |
|---|---|---|---|---|
| VAS, continuous | 0.343 | |||
| M (SD) | 66.6 (25.0) | 68.3 (24.9) | 65.0 (25.2) | |
| Median (Range) | 70 (50–90) | 80 (0–95) | 70 (0–100) | |
| Adherence | 0.692 | |||
| ≥90% | 27 (25.7) | 14 (27.5) | 13 (24.1) | |
| <90% | 78 (74.3) | 37 (72.6) | 41 (75.9) | |
| Age | 0.916 | |||
| M (SD) | 24.1 (2.9) | 24.1 (3.2) | 24.1 (2.7) | |
| Median (Range) | 23 (18–29) | 23 (18–29) | 23 (18–29) | |
| Log VL | 0.480 | |||
| M (SD) | 2.47 (1.41) | 2.48 (1.56) | 2.46 (1.25) | |
| Median (Range) | 1.68 (1.30–5.98) | 1.68 (1.30–5.98) | 1.61 (1.30–5.97) | |
| VL ≤75 copies/ml | 0.272 | |||
| Yes | 61 (65.6) | 34 (70.8) | 27 (60.0) | |
| No | 32 (34.4) | 14 (29.2) | 18 (40.0) | |
| Sex at birth | 0.608 | |||
| Male | 86 (81.9) | 41 (80.4) | 45 (83.3) | |
| Female | 18 (17.1) | 10 (19.6) | 8 (14.8) | |
| Intersex | 1 (1.0) | 0 (0.0) | 1 (1.9) | |
| Gender identity | 0.703 | |||
| Male | 84 (80.0) | 40 (78.4) | 44 (81.5) | |
| Female | 18 (17.1) | 10 (19.6) | 8 (14.8) | |
| Transgender M to F | 3 (2.9) | 1 (2.0) | 2 (3.7) | |
| Race/Ethnicity | 0.855 | |||
| White | 5 (4.8) | 3 (5.9) | 2 (3.7) | |
| Black | 78 (74.3) | 39 (76.5) | 39 (72.2) | |
| Hispanic | 8 (7.6) | 3 (5.9) | 5 (9.3) | |
| Other | 14 (13.3) | 6 (11.8) | 8 (14.8) | |
| Education | 0.329 | |||
| < HS | 14 (13.3) | 9 (17.7) | 5 (9.3) | |
| HS or GED | 25 (23.8) | 11 (21.6) | 14 (25.9) | |
| Some college | 48 (45.7) | 20 (39.2) | 28 (51.9) | |
| Associates degree/Trade school | 8 (7.6) | 6 (11.8) | 2 (3.7) | |
| Bachelor’s degree or higher | 10 (9.5) | 5 (9.8) | 5 (9.3) | |
| Ever received AFDC/TANF | 0.976 | |||
| Yes | 72 (71.3) | 35 (71.4) | 37 (71.2) | |
| No | 29 (28.7) | 14 (28.6) | 15 (28.9) | |
| Mode of Infection | 0.700 | |||
| Behavioral | 86 (81.9) | 40 (78.4) | 46 (85.2) | |
| Perinatal | 10 (9.5) | 6 (11.8) | 4 (7.4) | |
| Other | 9 (8.6) | 5 (9.8) | 4 (7.4) | |
| Completed 3 month follow-up | 0.090 | |||
| Yes | 94 (89.5) | 43 (84.3) | 51 (94.4) | |
| No | 11 (10.5) | 8 (15.7) | 3 (5.6) | |
| Completed 6 month follow-up | 0.318 | |||
| Yes | 92 (87.6) | 43 (84.3) | 49 (90.7) | |
| No | 13 (12.4) | 8 (15.7) | 5 (9.3) | |
| Marijuana use (ASSIST) | 0.398 | |||
| Moderate-High risk | 51 (60.7) | 23 (56.1) | 28 (65.1) | |
| Low risk | 33 (39.3) | 18 (43.9) | 15 (34.9) | |
| Depression | ||||
| BSI Depression Score, M (SD) | 59.4 (11.2) | 59.7 (12.3) | 59.2 (10.2) | 0.773 |
| BSI >63, n (%) | 43 (41.0) | 22 (43.1) | 21 (38.9) | 0.658 |
| BSI ≤63, n (%) | 62 (59.0) | 29 (56.9) | 33 (61.1) | |
| Medications | ||||
| Number of ARVs, M (SD) | 2.1 (1.0) | 2.5 (1.0) | 1.8 (1.0) | 0.002 |
| ≥ 2 meds vs. 1, n (%) | 64 (61.1) | 39 (76.5) | 25 (46.3) | 0.002 |
| Total drug duration in months, M (SD) | 23.7 (42.7) | 21.3 (27.7) | 25.9 (53.3) | 0.496 |
a
Column totals may not sum to 105 due to missing data.
b
Assessed by Wilcoxon test for non-normally distributed continuous variables and Chi-Square tests for categorical variables (Fisher’s exact Chi-Square test where appropriate).
Abbreviations: VAS Visual Analogue Scale; VL viral load; M mean; SD standard deviation; ASSIST Alcohol, Smoking, Substance Involvement Screening Test, BSI Brief Symptom Inventory, AFDC/TANF AIDS for Families with Dependent Children/Temporary Assistance for Needy Families